XML 36 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows (USD $)
 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Cash flows from operating activities:    
Net loss $ (49,459,277) $ (1,135,476)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 29,879  
Amortization of debt discount recorded as interest expense 1,952,309  
Stock-based compensation expense 15,720,011  
Unrealized foreign exchange gain   (2,626)
Change in fair value of derivative (10,093)  
Changes in operating assets and liabilities    
Prepaid expenses (539,761) 7,125
Accounts payable 658,863  
Accrued expenses and other liabilities (682,549) 180,919
Accrued collaborative expenses 1,386,493  
Net cash used in operating activities (30,944,125) (950,058)
Cash flows from investing activities:    
Cash acquired in business combination 1,167,869  
Purchases of equipment (33,739)  
Net cash provided by investing activities 1,134,130  
Cash flows from financing activities:    
Proceeds from working capital loans 1,882,817  
Repayments of working capital loans (1,882,817)  
Proceeds from sales of common stock in initial public offering 31,334,702  
Proceeds from sales of common stock in private placements 23,706,118 1,850,000
Fees paid in connection with private placements (280,000)  
Public offering costs paid (3,129,584)  
Net cash provided by financing activities 51,631,236 1,850,000
Net increase in cash and cash equivalents 21,821,241 899,942
Cash and cash equivalents    
Beginning of period 1,818,317 200,314
End of period 23,639,558 1,100,256
Supplemental disclosure of noncash investing and financing activities    
Common stock issued as consideration for business acquisition 16,541,834  
Plus liabilities assumed:    
Accrued expenses and other 321,417  
ProteoSys milestone payable 681,600  
Deferred tax liability 5,970,560  
Less assets acquired:    
Prepaid expenses 42,926  
Equipment 28,204  
In-process research and development 15,200,000  
Goodwill 7,076,412  
Cash acquired in business merger 1,167,869  
Incurred but unpaid public offering costs 10,250  
Conversion of debt and interest to common stock $ 2,112,000